Characterizing Cannabinoid CB2 Receptor Ligands Using DiscoveRx PathHunter™ β-Arrestin Assay

被引：49

作者：

Mcguinness, Debra ^{[1
]}

Malikzay, Asra ^{[1
]}

Visconti, Richard ^{[1
]}

Lin, Karen ^{[1
]}

Bayne, Marvin ^{[1
]}

Monsma, Frederick ^{[1
]}

Lunn, Charles A. ^{[1
]}

机构：

[1] Schering Plough Corp, Res Inst, New Lead Discovery, Kenilworth, NJ 07033 USA

来源：

JOURNAL OF BIOMOLECULAR SCREENING | 2009年 / 14卷 / 01期

关键词：

cannabinoid CB2 receptor; beta-arrestin; complementation; signal transduction; BONE MASS; CHEMOTAXIS; ACTIVATION; CELLS; AGONISTS; 2-ARACHIDONOYLGLYCEROL; MODULATION;

D O I：

10.1177/1087057108327329

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

The authors have characterized a set of cannabinoid CB2 receptor ligands, including triaryl bis sulfone inverse agonists, in a cell-based receptor/beta-arrestin interaction assay (DiscoveRx PathHunter (TM)). The results were compared with results using a competitive ligand binding assay, and with effects on forskolin-stimulated cAMP levels (PerkinElmer LANCE (TM)). The authors show good correlation between the 3 assay systems tested, with the beta-arrestin protein complementation assay exhibiting a more robust signal than the cAMP assay for cannabinoid CB2 agonists. Further assay validation shows that DiscoveRx PathHunter (TM) HEK293 CB2 beta-arrestin assay can be carried out from cryopreserved cell suspensions, eliminating variations caused by the need for multiple cell pools during live cell screening campaigns. These results, and the authors' results evaluating a test set of random library compounds, validate the use of ligand-induced interaction between the human cannabinoid CB2 receptor and beta-arrestin as an appropriate and valuable screening platform for compounds specific for the cannabinoid CB2 receptor. (Journal of Biomolecular Screening 2009:49-58)

引用

页码：49 / 58

页数：10

共 30 条

[11]

Kent T, 2007, CURR OPIN DRUG DISC, V10, P580

[12] Chemotaxis of human peripheral blood eosinophils to 2-arachidonoylglycerol: Comparison with other eosinophil chemoattractants [J].

Kishimoto, Seishi ;

Oka, Saori ;

Gokoh, Maiko ;

Sugiura, Takayuki .

INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2006, 140 :3-7

[13] Application of division arrest technology to cell-based HTS: Comparison with frozen and fresh cells [J].

Kunapuli, P ;

Zheng, W ;

Weber, M ;

Solly, K ;

Mull, R ;

Platchek, M ;

Cong, M ;

Zhong, Z ;

Strulovici, B .

ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2005, 3 (01) :17-26

[14] Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils [J].

Kurihara, R ;

Tohyama, Y ;

Matsusaka, S ;

Naruse, H ;

Kinoshita, E ;

Tsujioka, T ;

Katsumata, Y ;

Yamamura, H .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (18) :12908-12918

[15] Optimization of triaryl bis-sulfones as cannabinoid-2 receptor ligands [J].

Lavey, Brian J. ;

Kozlowski, Joseph A. ;

Shankar, Bandarpalle B. ;

Spitler, James M. ;

Zhou, Guowei ;

Yang, De-Yi ;

Shu, Youlieng ;

Wong, Michael K. C. ;

Wong, Shing-Chun ;

Shih, Neng-Yang ;

Wu, Jie ;

McCombie, Stuart W. ;

Rizvi, Razia ;

Wolin, Ronald L. ;

Lunn, Charles A. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (13) :3760-3764

[16] New roles for β-arrestins in cell signaling:: Not just seven-transmembrane receptors [J].

Lefkowitz, Robert J. ;

Rajagopal, Keshava ;

Whalen, Erin J. .

MOLECULAR CELL, 2006, 24 (05) :643-652

[17] Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists [J].

Lunn, C. A. ;

Reich, E-P ;

Fine, J. S. ;

Lavey, B. ;

Kozlowski, J. A. ;

Hipkin, R. W. ;

Lundell, D. J. ;

Bober, L. .

BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 (02) :226-239

[18] A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo [J].

Lunn, CA ;

Fine, JS ;

Rojas-Triana, A ;

Jackson, JV ;

Fan, XD ;

Kung, TT ;

Gonsiorek, W ;

Schwarz, MA ;

Lavey, B ;

Kozlowski, JA ;

Narula, SK ;

Lundell, DJ ;

Hipkin, RW ;

Bober, LA .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 316 (02) :780-788

[19] Cannabinoid CB2-selective inverse agonist protects against antigen-induced bone loss [J].

Lunn, Charles A. ;

Fine, Jay ;

Rojas-Triana, Alberto ;

Jackson, James V. ;

Lavey, Brian ;

Kozlowski, Joseph A. ;

Hipkin, R. William ;

Lundell, Daniel J. ;

Bober, Loretta .

IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2007, 29 (3-4) :387-401

[20] Targeting the CB2 receptor for immune modulation [J].

Lunn, Charles A. ;

Reich, Eva-Pia ;

Bober, Loretta .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2006, 10 (05) :653-663

← 1 2 3 →